Trump’s Recent Deal with Big Pharma: Lower Costs, But at What Cost?
Recently, President Trump signed another agreement, this time with a major pharmaceutical company, aimed at reducing costs for patients in the U.S. The industry is urging collaboration to support consumers and boost domestic production. Ironically, however, these same companies have raised prices across the board. Since the beginning of the year, about 700 prescription drugs have seen price hikes.
It seems that Big Pharma is hoping that this unorthodox presidency will revert to more traditional policies, granting major corporations regulatory benefits and taxpayer-funded advantages—essentially allowing them to maintain their increasing prices.
“We need to expose the games Big Pharma has been playing for years and force the industry to compete in real markets,” I think. It’s essential to address this.
Trump’s instincts have some merit. Americans are facing exorbitant prices, and he has indeed advocated against industry excesses. Still, these pharmaceutical giants have entrenched their interests deeply, benefitting from a kind of regulatory capture that few other sectors have achieved. They continue to raise prices while concealing a system that leads to further escalations in costs.
The strategies they employ are not surprising. With the backing of Trump’s administration, a large pharmaceutical company announced a partnership that ensured government contracts and political protection for their products. Independent analysts have cautioned that the rebate system actually encourages price hikes. This mirrors tactics used by retailers who inflate their listed prices before sales events to create a false sense of discounts.
There’s potential for the federal government to intervene and create a more balanced playing field. Currently, the regulations favor large pharmaceutical companies, which stifles competition and keeps patient costs high.
Patients Bear the Burden
The so-called reforms proposed by the industry often serve merely to shield profits while penalizing patients. The FDA introduced an “expedited approval” pathway for important treatments, but in reality, this primarily benefits larger companies. A recent study indicated that FDA regulation is on the rise, with sales for small and mid-sized firms taking a hit, while those for larger firms remain relatively unaffected. Small manufacturers struggle to meet high compliance costs, which means that more affordable drugs may never reach the market or can be delayed significantly.
At the end of the day, patients are left paying the price. Follow-up studies for drugs that were fast-tracked often yield disappointing results, with many therapies emerging years late— and lacking evident benefits. Research from Harvard found that nearly half of early-approved cancer treatments were ineffective at improving survival or quality of life. The FDA has revoked approval for one in four of these drugs, while a mere 12% of remaining drugs generate substantial revenue despite costing patients dearly.
Meanwhile, prices continue to climb. Since Trump’s departure from office, costs for cancer treatment medications have soared, outpacing inflation seen under Biden. New drugs’ median list prices have more than doubled, exceeding $300,000 annually from 2021 to 2024. In 2023 alone, pharmaceutical companies raised their prices by 35%. A report from the RAND Corporation revealed that Americans collectively shelled out over $600 billion in 2022 for prescriptions—almost three times higher than what patients in other developed nations pay.
Seeking Genuine Competition
Despite reports of record profits for Pharma companies, families grappling with cancer often face unsustainable out-of-pocket expenses. Trump deserves acknowledgment for recognizing the detrimental effects of unfair practices and specific policies that have driven drug prices beyond what most households can afford.
The solution lies in fostering true competition, not political favoritism. By leaning into market forces and reducing barriers to entry, Trump could help shatter the façade of the pharmaceutical industry’s dominance, encouraging a fairer environment for new players. The goal should be to force Big Pharma to operate in a real marketplace, not the manipulated framework they’ve maintained for years.
